Reagent Resource Support Program for AIDS Vaccine Development

艾滋病疫苗研发试剂资源支持计划

• 批准号: 10818316
• 负责人: VALERIE FREMONT
• 金额: $ 318.49万
• 依托单位: QUALITY BIOLOGICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-08 至 2024-04-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10818316
• 关键词: AIDS Vaccines; Acquired Immunodeficiency Syndrome; Biological Assay; Clinical; Cloning; Contractor; Contracts; Development; Equipment and supply inventories; Funding; Genetic; HIV vaccine; Local Microbicides; Maintenance; Mission; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Nongovernmental Organizations; Peptides; Quality Control; Reagent; Research Personnel; Research Priority; Resources; Services; United States National Institutes of Health; Vaccine Adjuvant; Vaccine Research; Viral Proteins; Virus; cytokine; novel; polyclonal antibody; pre-clinical; programs; quality assurance; reagent testing; vaccine development; vaccine immunogenicity; vaccine safety; vector vaccine

The discovery and development of an HIV/AIDS vaccine remains among the highest research priorities of the National Institute of Allergy and Infectious Diseases (NIAID), and is a principal mission of NIAID’s Division of AIDS (DAIDS). To support this mission, NIAID has provided high-quality, novel, and targeted reagents, assays and services for investigators engaged in AIDS vaccine-related research, including NIAID-funded grantees and contractors, other NIH-funded researchers, and investigators supported through various Non-Governmental Organizations (NGOs). These services are provided through this contract by investigator request and NIAID staff approval.

HIV/艾滋病疫苗的发现和开发仍然是国家过敏和传染病研究所 (NIAID) 的最高研究重点之一，也是 NIAID 艾滋病部门 (DAIDS) 的主要使命。为从事艾滋病疫苗相关研究的研究人员提供高质量、新颖和有针对性的试剂、测定和服务，包括 NIAID 资助的受赠者和承包商、其他 NIH 资助的研究人员以及通过以下方式支持的研究人员各种非政府组织 (NGO) 经研究者请求并经 NIAID 工作人员批准通过本合同提供。